sellWeak10b5-1 plan
Dana Pizzuti sold $781k of CRNX
Chief Med and Dev Officer at Crinetics Pharmaceuticals, Inc.. 15,000 shares at an average of $52.09, traded Jan 3, 2025, filed Jan 7, 2025.
Warning score
12Value
$781k
15,000 shares
Holdings after
29,248
-34% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +22Trade size$781k at market
- +10Share of holdings soldSold 34% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-002869, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 3, 2025 | MOption exercise Common Stock10b5-1 | +15,000 | $16.89 | $253k | 44,248 | Jan 7, 2025 |
| Jan 3, 2025 | SOpen-market sale Common Stock10b5-1 | -15,000 | $52.09 | $781k | 29,248 | Jan 7, 2025 |
| Jan 7, 2025 | MOption exercise Common Stock10b5-1 | +2,500 | $19.64 | $49k | 31,748 | Jan 7, 2025 |
| Jan 3, 2025 | MOption exercise Stock option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 124,042 | Jan 7, 2025 |
| Jan 7, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,500 | $0.00 | $0 | 18,500 | Jan 7, 2025 |
Related signals
Other insiders at Crinetics Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | $120k 3,000 shares | -13% | |
| 28Weak | Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | $246k 6,900 shares | -52% | |
| 15Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Dev. & Operating Officer | $3.4M 85,163 shares | -45% | |
| 26Weak | Crinetics Pharmaceuticals, Inc. | Stephen F. Betz Chief Scientific Officer | $397k 10,612 shares | -7% | |
| 43Moderate | Crinetics Pharmaceuticals, Inc. | Richard Scott Struthers President & CEO | $822k 21,981 shares | -5% | |
| 30Weak | Crinetics Pharmaceuticals, Inc. | Jeff E. Knight Chief Operating Officer | $370k 9,911 shares | -8% | |
| 27Weak | Crinetics Pharmaceuticals, Inc. | Coelho Rogerio Vivaldi director | $181k 5,000 shares | -23% | |
| 30Weak | Crinetics Pharmaceuticals, Inc. | Tobin Schilke Chief Financial Officer | $266k 6,713 shares | -8% | |
| 25Weak | Crinetics Pharmaceuticals, Inc. | Stephanie Okey director | $119k 3,000 shares | -18% | |
| 11Weak | Crinetics Pharmaceuticals, Inc. | Isabel Kalofonos Chief Commercial Officer | $138k 2,500 shares | -75% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.